Hormone replacement therapy in women treated for gynaecological malignancy

Maturitas

Volumn 32, Issue 2, 1999, Pages 69-76

  Burger, Curt W ^a   Van Leeuwen, Flora E ^b   Scheele, Fedde ^c   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Estrogen; Hormone replacement therapy; Progestogen

Indexed keywords

ESTROGEN; GESTAGEN;

CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CARDIOVASCULAR DISEASE; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LEIOMYOSARCOMA; NONHUMAN; OVARY CANCER; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; REVIEW;

EID: 0033052451     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00113-3     Document Type: Article

References (34)

1. Rosen P.P., Groshen S., Kinne D.W., Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J. Clin. Oncol. 11:1993;2090-2100.
2. Grodstein F., Stampfer M., Colditz G.A. et al. Postmenopausal hormone replacement therapy and mortality. New Engl. J. Med. 336(25):1997;1769-1775.
3. Stampfer M.J., Colditz G.A Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the nurses heath study. New Engl. J. Med. 325:1991;756-762.
4. Beral V., Bull D., Doll R., Dey T., Pero R., Reeves G. et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350(9084):1997;1047-1059.
5. Netherlands Cancer Registry. Incidence of cancer in the Netherlands 1994: 4th report of the Netherlands Cancer Registry, 1994.
6. Burger C.W., Koomen I., Peters N.A.J.B., Leeuwen F.E., van Kenemans P. Postmenopausal hormone replacement therapy and cancer of the female genital tract and the breast. Eur. Menopause J. 4(1):1997;23.
7. Burger C.W., Kenemans P. Postmenopausal hormone replacement therapy and cancer of the female genital tract and the breast. Curr. Opin. Obstet. Gynecol. 10:1998;41-45.
8. Whittaker G.K., Lee R.B., Benson W.L. Carcinoma of the endometrium in young women. Milit. Med. 151:1986;25.
9. Creasman W.T., Henderson D., Hinshaw W., Clarke-Pearson D.L. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet. Gynecol. 67:1986;326-330.
10. Lee R.B., Burke T.W., Park R.C. Estrogen replacement therapy following treatment for stage I endometrial cancer. Gynaecol. Oncol. 36:1990;189-191.
11. Chapman J.A., Berman M.L., Gilotte D.L., Roth P.D., Osann K., DiSaia P.K. Estrogen replacement therapy in surgical stage I and II endometrial cancer survivors. Am. J. Obstet. Gynecol. 175:1996;1195-1200.
12. Baker D.D. Estrogen replacement therapy in patient with previous endometrial carcinoma. Comp. Ther. 16:1990;28-35.
13. Bryant G.W. Administration of estrogen to patients with a previous diagnosis of endometrial adenocarcinoma. South Med. J. 83:1990;725-726.
14. Beresford S.A.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet. 349:1997;458-461.
15. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int. J. Cancer. 67:1996;327-332.
16. van derVange N., Greggi S., Burger C.W., Kenemans P., Vermorken J.B. Experience with hormonal therapy in advance epithelial ovarian cancer. Acta Oncol. 34(6):1995;813-820.
17. Lauritzen C. Oestrogensubstitution in der Postmenopause vor und nach behandeltem Genital- und Mammakarzinom. Lauritzen C. Menopause Hormonsubstitution heute. 1993;76-88 Aesopus Verlag, Basel.
18. Hempling R.E., Wong C., Piver M.S., Natarajan N., Mettlin C.J. Hormone replace therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet. Gynecol. 89:1997;1012-1016.
19. Colombo N., Chiari S., Maggioni A., Bocciolone L., Torri V., Maggioni C. Controversial issues in the management of early ovarian epithelial cancer: conservative surgery and role of adjuvant therapy. Gynecol. Oncol. 55:1994;47-51.
20. Fishman D.A., Schwartz P.E. Current approaches to diagnosis and treatment of ovarian cancer germ cell malignancies. Curr. Opin. Obstet. Gynecol. 6:1994;98-104.
21. Eeles R.A., Tan S., Wiltshaw E. et al. Hormone replacement therapy and survival after surgery for ovarian cancer. Br. Med. J. 302:1991;259-262.
22. Rao B.R., Slotman B.J. Endocrine role in ovarian cancer. Endocr. Relat. Cancer. 3(4):1996;309-326.
23. Wren B.G. Hormonal therapy following female genital tract cancer. Int. J. Gynecol. Cancer. 4:1994;217-224.
24. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 26:1987;169-177.
25. Smith E.M., Turek L.P., Haugen T.H. et al. The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy. Gynecol. Oncol. 65/3:1997;441-446.
26. Jones M.W., Silverberg S.G. Cervical adenocarcinoma in young women: possible relationships to microglandular hyperplasia and use of oral contraceptives. Obstet. Gynecol. 73(6):1989;984-989.
27. Wade K., Quinn M.A., Hammond I., Williams K., Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol. Oncol. 39:1990;364-367.
28. Navorro D., Cabrera J.J., Lean L. et al. Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen induced srp27 (24K) suggests hormone responsiveness. J. Steroid Biochem. Mol. Biol. 41(3-8):1992;589-596.
29. Schwartz S.M., Weiss N.S., Daling J.R. et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer. 77(4):1996;717-724.
30. Kenemans P., Scheele F. Hormone replacement therapy in patients with a history of breast cancer: risk and options. Eur. Menopause J. 3(2):1996;99-105.
31. Kenemans P., Stampfer M. Hormone replacement therapy and breast cancer. Eur. J. Obstet. Gynaecol. Reprod. Biol. 67:1996;1-4.
32. Kenemans P., Scheele F., Burger C.W. Hormone replacement therapy and breast cancer morbidity, mortality, and recurrence. Eur. J. Obstet. Gynaecol. Reprod. Biol. 71:1997;199-203.
33. Fuchs-Young R., Howe S., Hale L., Miles R., Walker C. Inhibition of estrogen-stimulated growth of uterine leimyomas by selective estrogen receptor modulators. Mol. Carcinog. 17(3):1996;151-159.
34. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR, Bryant, HU. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]-2-(4-hydroxyphenyl)]benzo[b]thiopene: a novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 1997;40(10)1407-16.